AI is making drug discovery look increasingly like software: faster, cheaper, and more powerful with every generation of models.But the rest of drug development has not moved at the same speed.
AI can now design and identify promising drug candidates faster than ever, while the path through clinical development remains narrow, expensive, and uncertain. If discovery becomes dramatically easier, the bigger question is where the bottleneck moves next, and where the value moves with it.
As part of DeepTech Week, Grove Ventures and ARC Innovation at Sheba Medical Center are bringing together biotech founders and industry leaders to examine where AI is genuinely changing biology, where fundamental constraints remain, and what will define the next generation of biotech companies.
From proprietary data and new business models to clinical translation and Israel’s unique healthcare infrastructure, we’ll explore what happens when AI removes one bottleneck and exposes the next.
If you’re building at the intersection of AI, biology, healthcare, or drug development, this is a conversation you’ll want to be part of.
